Botulax 100 IU is a botulinum toxin type A preparation designed for the temporary reduction of dynamic facial wrinkles by targeted relaxation of underlying muscles. It offers a clinical efficacy and diffusion profile comparable to onabotulinumtoxinA (Botox®), ensuring predictable and consistent results.
Each vial contains 100 units of Clostridium botulinum type A toxin, vacuum-dried and stabilized with human serum albumin and sodium chloride. Upon reconstitution with sterile saline, the solution provides smooth, even diffusion, enabling precise muscle targeting and natural facial expression.
The product is suitable for use in the glabellar region, forehead, crow’s feet, and nasolabial or perioral areas, as well as for masseter reduction or neck contour improvement, when applied by trained professionals. Clinical effect typically appears within 3–5 days, with full results at 1–2 weeks, and lasts up to 4–6 months, depending on dosage and muscle activity.
Storage & handling
Store unopened vials at 2°C–8°C (refrigerated).
Reconstituted solution should be used immediately and not stored.
Single-use vial — discard any unused portion.
Handle under aseptic conditions; dispose of all materials as medical waste.
For use by licensed medical professionals only. Not intended for self-administration or cosmetic home use.
Patients should avoid alcohol for 24–48 hours before and after injection to minimize bruising or bleeding at the injection sites.
Use is not recommended during lactation, as it is unknown whether botulinum toxin or its metabolites are excreted into breast milk.
Reconstitute one vial (100 units) with 2.5 ml of sterile 0.9% sodium chloride, yielding 4 units per 0.1 ml. The exact dose should be adjusted individually according to muscle mass, desired effect, and practitioner experience.
Typical dosage examples:
Glabellar lines: 20 units (4 units per injection site × 5 points)
Forehead lines: 10–20 units
Crow’s feet: 12–24 units (6–12 units per side)
Masseter reduction: 25–30 units per side
Use a fine 30G or 32G needle for intramuscular injection under aseptic conditions. Avoid intravascular injection.
Common reactions include mild erythema, swelling, bruising, or tenderness at the injection site, usually resolving within several days. Rare but serious adverse effects, such as ptosis, asymmetry, or flu-like symptoms, may occur if the toxin diffuses beyond the intended area. Injection should be performed only by licensed practitioners familiar with facial anatomy and botulinum toxin administration.
Botulax blocks the release of acetylcholine at the neuromuscular junction, preventing transmission of nerve impulses to the muscle. As a result, the injected muscle relaxes temporarily, reducing the appearance of wrinkles formed by repetitive facial movements. Over time, new synaptic connections form, and muscle activity gradually returns.
Use is contraindicated during pregnancy. There are no adequate and well-controlled studies on the safety of botulinum toxin in pregnant women. Treatment should be postponed until after delivery.
Each vial contains:
Clostridium botulinum type A toxin, 100 units
Human serum albumin (0.5 mg)
Sodium chloride (0.9 mg)
No animal-derived components are used in production.
